163 related articles for article (PubMed ID: 19563031)
1. [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):26-8. PubMed ID: 19563031
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia].
Zhang YL; Zhao WL; Nie SS; Guo DD; Ji ZH; Chai YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1496-500. PubMed ID: 22169311
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study.
Horibe K; Hara J; Yagi K; Tawa A; Komada Y; Oda M; Nishimura S; Ishikawa Y; Kudoh T; Ueda K
Int J Hematol; 2000 Jul; 72(1):61-8. PubMed ID: 10979211
[TBL] [Abstract][Full Text] [Related]
7. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
Karrman K; Forestier E; Heyman M; Andersen MK; Autio K; Blennow E; Borgström G; Ehrencrona H; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Kerndrup G; Nordgren A; Palmqvist L; Johansson B; ; ;
Genes Chromosomes Cancer; 2009 Sep; 48(9):795-805. PubMed ID: 19530250
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
11. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
[TBL] [Abstract][Full Text] [Related]
13. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
14. Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols.
Andersen MK; Autio K; Barbany G; Borgström G; Cavelier L; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Johansson B; Kjeldsen E; Nordgren A; Palmqvist L; Forestier E
Br J Haematol; 2011 Oct; 155(2):235-43. PubMed ID: 21902680
[TBL] [Abstract][Full Text] [Related]
15. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
16. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
[TBL] [Abstract][Full Text] [Related]
17. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
19. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
